PREDICTIVE FACTORS FOR LOSS OF RESPONSE TO ANTI-TNF IN CROHN’S DISEASE

PREDICTIVE FACTORS FOR LOSS OF RESPONSE TO ANTI-TNF IN CROHN’S DISEASE

ABSTRACT Background: Anti-TNF drugs are a fundamental part of the treatment of Crohn’s disease (CD), so identifying factors related to loss of response is of great importance in clinical practice. Aim: Identify potential factors related to loss of response to anti-TNF agents in Crohn’s disease patie...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Byanca Rossetti Moreira Dos SANTOS, SANTOS, Carlos Henrique Marques Dos, SANTOS, Vitória Rossetti Moreira Dos, TORREZ, Claudia Yanina Garcia, PALOMARES-JUNIOR, Daniel
Format: Dataset
Sprache:eng
Schlagworte:
FOS: Clinical medicine
Gastroenterology and Hepatology
Surgery
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page
container_title
container_volume
creator Byanca Rossetti Moreira Dos SANTOS
SANTOS, Carlos Henrique Marques Dos
SANTOS, Vitória Rossetti Moreira Dos
TORREZ, Claudia Yanina Garcia
PALOMARES-JUNIOR, Daniel
description ABSTRACT Background: Anti-TNF drugs are a fundamental part of the treatment of Crohn’s disease (CD), so identifying factors related to loss of response is of great importance in clinical practice. Aim: Identify potential factors related to loss of response to anti-TNF agents in Crohn’s disease patients. Methods: This is a prospective study of CD patients attending a specialized outpatient clinic using a specific form, including patients with more than one year of follow-up on anti-TNF (Infliximab, Adalimumab or Certolizumab pegol). The information obtained was tabulated and analyzed to identify possible reasons for the loss of response to anti-TNF agents; results were submitted to statistical analysis by chi-square teste considering significant p
doi_str_mv 10.6084/m9.figshare.14281492
format Dataset
fullrecord <record><control><sourceid>datacite_PQ8</sourceid><recordid>TN_cdi_datacite_primary_10_6084_m9_figshare_14281492</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>10_6084_m9_figshare_14281492</sourcerecordid><originalsourceid>FETCH-LOGICAL-d912-20ed99b26159dde9cea78103c7111c9d1f7f107ba095c81dbf51331cee06f1353</originalsourceid><addsrcrecordid>eNo1z01KxDAYgOFsXMjoDVzkAq35mv5lWTqpDZRmSILbkOZHCxakMxt3XsPreRIRndW7e-FB6AFIXpO2fNxYntaX86vbYw5l0ULJils0nhQ_it6IZ46HrjdSaTxIhSepNZYDVlyf5Kw5NhJ3sxGZmQcsZtwrOc7fn18aH4XmneZ36Ca5t3O8_-8BmYGbfswm-ST6bsoCgyIrSAyMLUUNFQshMh9d0wKhvgEAzwKkJgFpFkdY5VsIS6qAUvAxkjoBregBlX_b4C7Or5do3_d1c_uHBWJ_nXZj9uq0Vyf9AWvGSQ0</addsrcrecordid><sourcetype>Publisher</sourcetype><iscdi>true</iscdi><recordtype>dataset</recordtype></control><display><type>dataset</type><title>PREDICTIVE FACTORS FOR LOSS OF RESPONSE TO ANTI-TNF IN CROHN’S DISEASE</title><source>DataCite</source><creator>Byanca Rossetti Moreira Dos SANTOS ; SANTOS, Carlos Henrique Marques Dos ; SANTOS, Vitória Rossetti Moreira Dos ; TORREZ, Claudia Yanina Garcia ; PALOMARES-JUNIOR, Daniel</creator><creatorcontrib>Byanca Rossetti Moreira Dos SANTOS ; SANTOS, Carlos Henrique Marques Dos ; SANTOS, Vitória Rossetti Moreira Dos ; TORREZ, Claudia Yanina Garcia ; PALOMARES-JUNIOR, Daniel</creatorcontrib><description>ABSTRACT Background: Anti-TNF drugs are a fundamental part of the treatment of Crohn’s disease (CD), so identifying factors related to loss of response is of great importance in clinical practice. Aim: Identify potential factors related to loss of response to anti-TNF agents in Crohn’s disease patients. Methods: This is a prospective study of CD patients attending a specialized outpatient clinic using a specific form, including patients with more than one year of follow-up on anti-TNF (Infliximab, Adalimumab or Certolizumab pegol). The information obtained was tabulated and analyzed to identify possible reasons for the loss of response to anti-TNF agents; results were submitted to statistical analysis by chi-square teste considering significant p&lt;0.05. Results: Sixty-four patients were included, most of them females (56.3%), predominant age group between 26 and 55 years, of whom 25 required optimization, 23 remained in remission with the usual dose and interval, and 16 required switch; most of those who needed switch had hematological problems such as anemia and/or had already undergone surgical treatment for CD. Conclusions: Anemia and prior CD surgery have been linked to loss of anti-TNF response.</description><identifier>DOI: 10.6084/m9.figshare.14281492</identifier><language>eng</language><publisher>SciELO journals</publisher><subject>FOS: Clinical medicine ; Gastroenterology and Hepatology ; Surgery</subject><creationdate>2021</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>780,1894</link.rule.ids><linktorsrc>$$Uhttps://commons.datacite.org/doi.org/10.6084/m9.figshare.14281492$$EView_record_in_DataCite.org$$FView_record_in_$$GDataCite.org$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>Byanca Rossetti Moreira Dos SANTOS</creatorcontrib><creatorcontrib>SANTOS, Carlos Henrique Marques Dos</creatorcontrib><creatorcontrib>SANTOS, Vitória Rossetti Moreira Dos</creatorcontrib><creatorcontrib>TORREZ, Claudia Yanina Garcia</creatorcontrib><creatorcontrib>PALOMARES-JUNIOR, Daniel</creatorcontrib><title>PREDICTIVE FACTORS FOR LOSS OF RESPONSE TO ANTI-TNF IN CROHN’S DISEASE</title><description>ABSTRACT Background: Anti-TNF drugs are a fundamental part of the treatment of Crohn’s disease (CD), so identifying factors related to loss of response is of great importance in clinical practice. Aim: Identify potential factors related to loss of response to anti-TNF agents in Crohn’s disease patients. Methods: This is a prospective study of CD patients attending a specialized outpatient clinic using a specific form, including patients with more than one year of follow-up on anti-TNF (Infliximab, Adalimumab or Certolizumab pegol). The information obtained was tabulated and analyzed to identify possible reasons for the loss of response to anti-TNF agents; results were submitted to statistical analysis by chi-square teste considering significant p&lt;0.05. Results: Sixty-four patients were included, most of them females (56.3%), predominant age group between 26 and 55 years, of whom 25 required optimization, 23 remained in remission with the usual dose and interval, and 16 required switch; most of those who needed switch had hematological problems such as anemia and/or had already undergone surgical treatment for CD. Conclusions: Anemia and prior CD surgery have been linked to loss of anti-TNF response.</description><subject>FOS: Clinical medicine</subject><subject>Gastroenterology and Hepatology</subject><subject>Surgery</subject><fulltext>true</fulltext><rsrctype>dataset</rsrctype><creationdate>2021</creationdate><recordtype>dataset</recordtype><sourceid>PQ8</sourceid><recordid>eNo1z01KxDAYgOFsXMjoDVzkAq35mv5lWTqpDZRmSILbkOZHCxakMxt3XsPreRIRndW7e-FB6AFIXpO2fNxYntaX86vbYw5l0ULJils0nhQ_it6IZ46HrjdSaTxIhSepNZYDVlyf5Kw5NhJ3sxGZmQcsZtwrOc7fn18aH4XmneZ36Ca5t3O8_-8BmYGbfswm-ST6bsoCgyIrSAyMLUUNFQshMh9d0wKhvgEAzwKkJgFpFkdY5VsIS6qAUvAxkjoBregBlX_b4C7Or5do3_d1c_uHBWJ_nXZj9uq0Vyf9AWvGSQ0</recordid><startdate>20210324</startdate><enddate>20210324</enddate><creator>Byanca Rossetti Moreira Dos SANTOS</creator><creator>SANTOS, Carlos Henrique Marques Dos</creator><creator>SANTOS, Vitória Rossetti Moreira Dos</creator><creator>TORREZ, Claudia Yanina Garcia</creator><creator>PALOMARES-JUNIOR, Daniel</creator><general>SciELO journals</general><scope>DYCCY</scope><scope>PQ8</scope></search><sort><creationdate>20210324</creationdate><title>PREDICTIVE FACTORS FOR LOSS OF RESPONSE TO ANTI-TNF IN CROHN’S DISEASE</title><author>Byanca Rossetti Moreira Dos SANTOS ; SANTOS, Carlos Henrique Marques Dos ; SANTOS, Vitória Rossetti Moreira Dos ; TORREZ, Claudia Yanina Garcia ; PALOMARES-JUNIOR, Daniel</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-d912-20ed99b26159dde9cea78103c7111c9d1f7f107ba095c81dbf51331cee06f1353</frbrgroupid><rsrctype>datasets</rsrctype><prefilter>datasets</prefilter><language>eng</language><creationdate>2021</creationdate><topic>FOS: Clinical medicine</topic><topic>Gastroenterology and Hepatology</topic><topic>Surgery</topic><toplevel>online_resources</toplevel><creatorcontrib>Byanca Rossetti Moreira Dos SANTOS</creatorcontrib><creatorcontrib>SANTOS, Carlos Henrique Marques Dos</creatorcontrib><creatorcontrib>SANTOS, Vitória Rossetti Moreira Dos</creatorcontrib><creatorcontrib>TORREZ, Claudia Yanina Garcia</creatorcontrib><creatorcontrib>PALOMARES-JUNIOR, Daniel</creatorcontrib><collection>DataCite (Open Access)</collection><collection>DataCite</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>Byanca Rossetti Moreira Dos SANTOS</au><au>SANTOS, Carlos Henrique Marques Dos</au><au>SANTOS, Vitória Rossetti Moreira Dos</au><au>TORREZ, Claudia Yanina Garcia</au><au>PALOMARES-JUNIOR, Daniel</au><format>book</format><genre>unknown</genre><ristype>DATA</ristype><title>PREDICTIVE FACTORS FOR LOSS OF RESPONSE TO ANTI-TNF IN CROHN’S DISEASE</title><date>2021-03-24</date><risdate>2021</risdate><abstract>ABSTRACT Background: Anti-TNF drugs are a fundamental part of the treatment of Crohn’s disease (CD), so identifying factors related to loss of response is of great importance in clinical practice. Aim: Identify potential factors related to loss of response to anti-TNF agents in Crohn’s disease patients. Methods: This is a prospective study of CD patients attending a specialized outpatient clinic using a specific form, including patients with more than one year of follow-up on anti-TNF (Infliximab, Adalimumab or Certolizumab pegol). The information obtained was tabulated and analyzed to identify possible reasons for the loss of response to anti-TNF agents; results were submitted to statistical analysis by chi-square teste considering significant p&lt;0.05. Results: Sixty-four patients were included, most of them females (56.3%), predominant age group between 26 and 55 years, of whom 25 required optimization, 23 remained in remission with the usual dose and interval, and 16 required switch; most of those who needed switch had hematological problems such as anemia and/or had already undergone surgical treatment for CD. Conclusions: Anemia and prior CD surgery have been linked to loss of anti-TNF response.</abstract><pub>SciELO journals</pub><doi>10.6084/m9.figshare.14281492</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext_linktorsrc
identifier DOI: 10.6084/m9.figshare.14281492
ispartof
issn
language eng
recordid cdi_datacite_primary_10_6084_m9_figshare_14281492
source DataCite
subjects FOS: Clinical medicine
Gastroenterology and Hepatology
Surgery
title PREDICTIVE FACTORS FOR LOSS OF RESPONSE TO ANTI-TNF IN CROHN’S DISEASE
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T11%3A49%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-datacite_PQ8&rft_val_fmt=info:ofi/fmt:kev:mtx:book&rft.genre=unknown&rft.au=Byanca%20Rossetti%20Moreira%20Dos%20SANTOS&rft.date=2021-03-24&rft_id=info:doi/10.6084/m9.figshare.14281492&rft_dat=%3Cdatacite_PQ8%3E10_6084_m9_figshare_14281492%3C/datacite_PQ8%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true